PDF

摘要/Abstract

摘要：

背景与目的： 二线化疗方案治疗胃癌疗效欠佳，贝伐珠单抗属于抗血管生成分子靶向抗癌药物，信迪利单抗是一种国产的程序性死亡蛋白-1（programmed death-1，PD-1）抑制剂，两者结合是临床治疗胃癌的新方向。本研究旨在探究贝伐珠单抗辅助PD-1抑制剂治疗胃癌对血清miR-20a-5p和miR-515-3p的影响。方法： 选取2019年1月—2021年7月于南京医科大学第四附属医院就诊的84例胃癌患者进行回顾性研究，根据治疗方案的不同将其分为观察组和对照组（每组各42例），对照组给予二线化疗方案治疗，观察组在对照组基础上给予贝伐珠单抗联合PD-1抑制剂（信迪利单抗）治疗，比较两组的客观缓解率（objective response rate，ORR）、疾病控制率（disease control rate，DCR）、血清肿瘤标志物、免疫功能指标、血清miR-20a-5p、miR-515-3p及不良反应总发生率。本研究已通过南京医科大学第四附属医院伦理委员会的伦理审批（批件号：20230531--K061）。结果： 观察组的ORR（69.05%）和DCR（85.71%）均高于对照组（40.48%、64.29%）。观察组治疗后的血清糖类抗原12-5（carbohydrate antigen 12-5，CA12-5）、癌胚抗原（carcinoembryonic antigen，CEA）及细胞角蛋白19片段抗原21-1（cytokerantin-19-fragment antigen 21-1，CYFRA21-1）水平均低于对照组。观察组治疗后的CD4⁺ T淋巴细胞、CD4⁺/CD8⁺ T淋巴细胞比值均高于对照组，CD8⁺ T淋巴细胞低于对照组，差异均有统计学意义（P<0.05）。观察组治疗后的血清miR-20a-5p、miR-515-3p水平均低于对照组，差异有统计学意义（P<0.05）。观察组（28.57%）的不良反应总发生率与对照组（38.10%）相比，差异无统计学意义（P>0.05）。结论： 贝伐珠单抗辅助信迪利单抗可有效地提高胃癌治疗效率，改善免疫功能，降低血清miR-20a-5p、miR-515-3p及肿瘤标志物表达量，且不会增加不良反应，效果显著。

关键词: 贝伐珠单抗, 程序性死亡蛋白-1抑制剂, 胃癌, miR-20a-5p, miR-515-3p

Abstract:

Background and purpose: Second-line chemotherapy is not effective in the treatment of gastric cancer. Bevacizumab is a molecularly targeted anticancer drug, and sindilizumab is a domestic programmed death-1 (PD-1) inhibitor. The combination of the two is a new direction for clinical treatment of gastric cancer. This study aimed to analyze the effects of bevacizumab assisted PD-1 inhibitor in the treatment of gastric cancer on serum miR-20a-5p and miR-515-3p. Methods: A retrospective study was conducted on 84 patients with gastric cancer treated in the Fourth Affiliated Hospital of Nanjing Medical University from January 2019 to July 2021, and they were divided into the observation group and the control group with 42 cases each according to different treatment plans. The control group was given second-line chemotherapy, and the observation group was given bevacizumab combined with PD-1 inhibitor (sindilizumab) on the basis of the control group. objective response rate (ORR), disease control rate (DCR), serum tumor markers, immune function indexes, serum miR-20a-5p and miR-515-3p levels and total incidence of toxic and side effects were compared between the two groups. This study has been approved by the Ethics Committee of the Fourth Affiliated Hospital of Nanjing Medical University (approval number: 20230531--K061). Results: The ORR (69.05%) and DCR (85.71%) of the observation group were higher than those of the control group (40.48% and 64.29%), and the difference was statistically significant (P<0.05). After treatment, serum carbohydrate antigen 12-5 (CA12-5), carcinoembryonic antigen (CEA) and cytokerantin-19-fragment antigen 21-1 (CYFRA21-1) levels were lower in observation group than in control group (P<0.05). CD4⁺ T lymphocyte and CD4⁺/CD8⁺ T lymphocyte ratio were higher in observation group than in control group after treatment (P<0.05), and CD8⁺ T lymphocyte was lower in observation group than in control group after treatment (P<0.05). After treatment, the serum levels of miR-20a-5p and miR-515-3p were lower in the observation group than in the control group (P<0.05). There was no significant difference in total incidence of adverse effects between the observation group (28.57%) and the control group (38.10%) (P>0.05). Conclusion: Bevacizumab assisted sindilizumab can effectively improve the treatment efficiency of gastric cancer, improve immune function, and reduce the expression levels of serum miR-20a-5p, miR-515-3p and tumor markers, without increasing toxic and side effects.

Key words: Bevacizumab, Programmed death-1 inhibitor, Gastric cancer, miR-20a-5p, miR-515-3p

中图分类号:

R735.2

汪斐, 刘佩, 胡楠. 贝伐珠单抗辅助PD-1抑制剂治疗胃癌对血清miR-20a-5p和miR-515-3p的影响研究[J]. 中国癌症杂志, 2024, 34(5): 493-500.

WANG Fei, LIU Pei, HU Nan. Effect of bevacizumab assisted PD-1 inhibitor on serum miR-20a-5p and miR-515-3p in the treatment of gastric cancer[J]. China Oncology, 2024, 34(5): 493-500.

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://www.china-oncology.com/CN/10.19401/j.cnki.1007-3639.2024.05.006

http://www.china-oncology.com/CN/Y2024/V34/I5/493

[1]	上海市抗癌协会胃癌专业委员会, 中国人体健康科技促进会胃肠肿瘤专业委员会. 侵犯邻近脏器的进展期胃癌的临床诊疗中国专家共识（2024年版）[J]. 中国癌症杂志, 2024, 34(5): 517-526.
[2]	许永虎, 徐大志. 21世纪以来胃癌治疗进展及未来展望[J]. 中国癌症杂志, 2024, 34(3): 239-249.
[3]	汪学非, 周鹏, 唐兆庆. 胃癌外科治疗的新进展及发展趋势[J]. 中国癌症杂志, 2024, 34(3): 250-258.
[4]	薛驰, 高鹏, 朱志, 王振宁. 免疫治疗在胃癌的围手术期及转化治疗中的应用和挑战[J]. 中国癌症杂志, 2024, 34(3): 259-267.
[5]	沈洁, 王江立, 王泽洲, 莫淼, 周昌明, 袁晶, 徐大志, 郑莹. 以大型单中心医院登记为基础的6 737例接受手术切除的胃癌患者的生存报告[J]. 中国癌症杂志, 2024, 34(3): 268-277.
[6]	李晶, 郑磊, 高钰. 曲妥珠单抗辅助改良DOF双周方案对顺铂耐药的胃癌患者血清肿瘤标志物及生存率的影响分析[J]. 中国癌症杂志, 2024, 34(3): 286-292.
[7]	孙洋, 王炼, 赵萌, 张小凤, 耿志军, 王月月, 宋雪, 左芦根, 李静, 胡建国. 胃癌中FKBP1A高表达的预后价值及其靶向PI3K/AKT对糖代谢的调控作用[J]. 中国癌症杂志, 2023, 33(8): 726-739.
[8]	康殷楠, 陈顺, 解有成, 郑英, 何昱静, 李初谊, 于晓辉. 抗体药物偶联物在HER2阳性晚期胃癌中的应用进展和展望[J]. 中国癌症杂志, 2023, 33(8): 790-800.
[9]	杜书祥, 赵英志, 张雪涛, 王涛, 骆晶钰, 张伟, 吴刚. 不同部位胃腺癌第12a组淋巴结转移的危险因素分析[J]. 中国癌症杂志, 2023, 33(6): 597-604.
[10]	邹婷, 刘晓文. 胃癌同时性肝转移肝切除的疗效及预后分析[J]. 中国癌症杂志, 2023, 33(6): 605-612.
[11]	蒋金玲, 周尘飞, 王超, 赵丽琴, 吴珺玮, 张俊. 2022年度胃癌研究和诊疗新进展[J]. 中国癌症杂志, 2023, 33(4): 303-314.
[12]	肖岚姝, 潘柳荻, 刘毅, 王洁, 陈惠. LncRNA DLEU7-AS1通过调控膜突蛋白MSN的表达促进胃癌细胞增殖与迁移的作用机制[J]. 中国癌症杂志, 2023, 33(4): 327-341.
[13]	彭进, 王伟宁, 谭智, 叶冠男, 周震. m6Am修饰酶PCIF1调控靶基因ACOT8参与胃癌进展的机制研究[J]. 中国癌症杂志, 2023, 33(4): 368-376.
[14]	刘洋, 胡奕炀, 刘月平, 牛淑瑶, 丁平安, 田园, 郭洪海, 杨沛刚, 张泽, 郑涛, 檀碧波, 范立侨, 李勇, 赵群. 人工智能辅助技术在胃癌新辅助化疗患者HER2表达评估中的价值[J]. 中国癌症杂志, 2023, 33(4): 377-387.
[15]	陈馨宁, 姜惠琴, 杨轶慧, 虞倩, 张春燕, 王蓓丽, 潘柏申, 郭玮. 血浆Septin9基因甲基化状态和水平在胃癌患者诊断和预后评估中的应用价值[J]. 中国癌症杂志, 2023, 33(2): 162-167.

贝伐珠单抗辅助PD-1抑制剂治疗胃癌对血清miR-20a-5p和miR-515-3p的影响研究

PDF

摘要/Abstract

引用本文

使用本文

相关文章